Growth Metrics

Gilead Sciences (GILD) Capital Expenditures (QoQ) (2009 - 2026)

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn
10 Gsk 88.34 Bn 83.66 Bn -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -42.93%
Dec 31, 2025 39.46%
Sep 30, 2025 37.38%
Jun 30, 2025 2.88%
Mar 31, 2025 -29.25%
Dec 31, 2024 4.26%
Sep 30, 2024 8.46%
Jun 30, 2024 23.81%
Mar 31, 2024 -51.16%
Dec 31, 2023 76.23%
Sep 30, 2023 -12.23%
Jun 30, 2023 27.52%
Mar 31, 2023 -39.78%
Dec 31, 2022 15.29%
Sep 30, 2022 9.79%
Jun 30, 2022 -42.11%
Mar 31, 2022 58.33%
Dec 31, 2021 12.23%
Sep 30, 2021 16.81%
Jun 30, 2021 -27.88%
Mar 31, 2021 -8.84%
Dec 31, 2020 16.77%
Sep 30, 2020 8.39%
Jun 30, 2020 -16.37%
Mar 31, 2020 -15.76%
Dec 31, 2019 1.50%
Sep 30, 2019 8.11%
Jun 30, 2019 -21.94%
Mar 31, 2019 -4.44%
Dec 31, 2018 48.50%
Sep 30, 2018 -43.77%
Jun 30, 2018 40.09%
Mar 31, 2018 -3.64%
Dec 31, 2017 70.54%
Sep 30, 2017 4.88%
Jun 30, 2017 4.24%
Mar 31, 2017 -30.18%
Dec 31, 2016 -14.65%
Sep 30, 2016 -2.94%
Jun 30, 2016 15.25%
Mar 31, 2016 6.63%
Dec 31, 2015 -41.96%
Sep 30, 2015 67.25%
Jun 30, 2015 37.90%
Mar 31, 2015 -25.75%
Dec 31, 2014 23.70%
Sep 30, 2014 48.35%
Jun 30, 2014 -44.51%
Mar 31, 2014 138.75%
Dec 31, 2013 84.75%
Sep 30, 2013 -17.88%
Jun 30, 2013 16.53%
Mar 31, 2013 -85.60%
Dec 31, 2012 305.24%
Sep 30, 2012 78.07%
Jun 30, 2012 61.18%
Mar 31, 2012 -11.15%
Dec 31, 2011 -59.39%
Sep 30, 2011 141.37%
Jun 30, 2011 79.12%
Mar 31, 2011 -36.35%
Dec 31, 2010 116.19%
Sep 30, 2010 -32.68%
Jun 30, 2010 37.59%
Mar 31, 2010 -56.77%
Dec 31, 2009 48.89%
Sep 30, 2009 -13.17%
Jun 30, 2009 -87.28%